ArticleJournal of surgery and research2025
A "Watchful Surgery" Approach: Timing and Valve Choice for Mildly Symptomatic Mitral and Aortic Valve Disease.
Article in Journal of surgery and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Rapid Treatment of Acute Decompensated Heart Failure with Cardiogenic Shock in the Emergency Setting.Cardiology and cardiovascular medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The timing of surgical intervention and prosthesis selection in mildly symptomatic aortic and mitral valve disease remain an area of clinical uncertainty. Symptom-based referral often occurs after the onset of adverse ventricular remodeling, whereas earlier surgery may improve long-term outcomes but introduces procedural risk. This article synthesized contemporary evidence to delineate optimal strategies in this intermediate-risk population. In aortic stenosis, randomized trials including RECOVERY and AVATAR demonstrate that early surgical aortic valve replacement reduces heart failure events and may improve survival. In aortic and mitral regurgitation, observational data associate early intervention, triggered by mild symptoms or subclinical ventricular dysfunction, with improved survival and preservation of cardiac function. Emerging modalities such as global longitudinal strain and natriuretic peptide biomarkers enhance risk stratification in asymptomatic individuals. Prosthesis selection is primarily informed by patient age, comorbidity burden, and anticoagulation tolerance. Mechanical valves confer superior durability and lower reoperation risk in younger patients. Bioprosthetic valves are increasingly favored in older adults due to compatibility with transcatheter valve-in-valve reintervention and avoidance of lifelong anticoagulation. Comparative cohort studies and meta-analyses suggest a survival benefit for mechanical valves up to approximately 65-to-70 years of age, beyond which the benefit diminishes due to competing mortality risks. Evidence supports timely surgical referral in mildly symptomatic patients, particularly in the presence of early imaging or biomarker evidence of ventricular dysfunction. Individualized decision-making through multidisciplinary heart team evaluation remains essential. Further investigations are warranted to define long-term prosthetic durability and the role of early surgery in valvular regurgitation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.